The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

Although the importance of CD4⁺ T cells for the induction of an effective CD8⁺ cytolytic T cell response is well documented, the mechanism by which MHC class II-negative tumor cells recruit CD4⁺ T help is not well understood. We have previously shown that IL-2 or IFN-γ gene-modified CMS-5 tumor cells do not grow in syngeneic mice; however, mice which rejected the cytokine-secreting tumor cells develop a protective immune response against a challenge with parental tumor cells. Here we show that rejection of IL-2- secreting CMS-5 cells is not mediated by T cells. However, establishment of a protective immune response against CMS-5 tumor cells requires the presence of both CD4⁺ and CD8⁺ T cell subsets during the period of immunization with IL-2-secreting CMS-5 cells as well as during the effector phase. Extensive histologic analysis has failed to detect the presence of T cells at the site of immunization with either IL-2- or IFN-γ-secreting CMS-5 cells. The main infiltrate at the site of inoculation with IL-2-secreting CMS-5 cells consisted of NK cells that appeared to play a role in their rejection. The predominant infiltrate at the site of inoculation with IFN-γ-secreting CMS- 5 cells consisted of macrophages. These observations argue against a direct role for the intact tumor cell in presenting either T helper or CTL epitopes to the immune system, and support the view that specialized APC are responsible for the in vivo priming of a T cell response against MHC class I- restricted Ag.